Health Robotics announced that Dr M Group has selected the CytoCare and i.v.STATION Robots to be deployed across all of its I.V. Compounding Centers in Malaysia, Singapore, Indonesia, Vietnam and India.

 

“After multi-year due diligence on two companies in the field of I.V. robotics, the doubts we had on this exciting new technology, and the large capital investment required to automate our I.V. Centers, these three factors demanded that we witnessed the real results of these IV Robots with actual hospital visits, rather than simply rely on vendors' stated vision or promises,” said Viswanathan Mukaya, CEO of Dr M Group, in a statement.

Mukaya said that he visited RIVA’s Children's Hospital of Orange County and Health Robotics' University of Colorado and Umberto I University Hospitals.

 

He said that after seeing real patient utilization, the company quickly decided to select Health Robotics due to their unique ability to compound both chemotherapy and non-hazardous I.V. Admixtures and much lower total cost of ownership.

 

Dr M Group is a privately-held conglomerate of business enterprises whose mission is to bring unique high-quality products and services to South East Asia and to elevate the quality of life standards in the countries it operates.

 

“I’m very pleased to maintain our 100 percent winning record in every competitive I.V. Robotics’ purchasing decision in the world since we launched the company in mid-2006. Obviously it’s an impossible record to forever maintain, but everyone in our company will certainly enjoy the winning record while it lasts,” stated Werner Rainer, Health Robotics’ CEO.

 

“I have tasked Gaspar DeViedma with the responsibility to manage Health Robotics' part of this exciting new joint venture in South East Asia, for which he will be partially relocating from Europe to Asia-Pacific during a yet to-be-determined period of time,” said Rainer.

 

He said that DeViedma will also oversee a future manufacturing expansion of the company in Asia-Pacific to cope with the sudden growth in the region that Health Robotics has experienced after the company successfully changed sales-channel strategies this Summer, including the NTUH direct intervention in Taiwan, and the soon to be announced Health Robotics’ new marketing and operations strategies in China, Australia and New Zealand.

Health Robotics is the global supplier of life-critical intravenous medication preparation, compounding, and dispensing Robots, providing healthcare facilities in four continents with robotics technology and software automation solutions.